The BCI category is broadening beyond motor restoration in 2026

By Inside BCI · July 13, 2026

Vancouver police sergeant Lee Marten received a transdural Neuralink implant at University Health Network’s Toronto Western Hospital in May 2026, becoming the first Canadian ALS patient in Neuralink’s CAN-PRIME trial and the first human anywhere to receive the N1 via Neuralink’s new transdural surgical technique. One of three patients at Royal Melbourne Hospital received a cortical implant from Coherence Neuro during tumour-resection surgery in June. Nia Therapeutics is preparing an Investigational Device Exemption application for a 60-channel closed-loop memory implant intended for adults with TBI-related persistent memory deficits; the target population Nia cites, per a 2015 US Centers for Disease Control and Prevention Report to Congress, is more than 4.3 million Americans. On the surface, three entirely different medical situations. Under the surface, they are three ends of a category that has widened significantly in 2026.

The clinical-stage brain-computer interface and neuromodulation field is no longer only about restoring motor function to people with paralysis. It is also about restoring memory in traumatic brain injury, restoring vision through cortical stimulation, preventing cerebral vasospasm in intensive care after aneurysmal rupture, monitoring and modulating brain tumor activity, restoring autonomic function like bladder control after spinal cord injury, treating treatment-resistant depression, and diagnosing covert consciousness in brain-injured patients who present as unresponsive.

The dominant BCI narrative from 2024 through the first quarter of 2026, driven by Neuralink’s cursor-and-typing milestones and Synchron’s endovascular motor cohort, was that BCI is a paralysis-restoration technology. That narrative is still true. It is also increasingly incomplete. Across the first half of 2026 and the first weeks of the second half, at least three US Food and Drug Administration Breakthrough Device Designations, three first-in-human or investigational-device clinical milestones, and two significant peer-reviewed publications extended the category into non-motor indications that carry substantially larger addressable patient populations and substantially harder governance conversations than the classical motor-restoration lane. Inside BCI is reading the pattern as the vertical broadening, not the motor lane rotating out. The motor pipeline itself expanded in the same window, and the motor lane remains the anchor of the field in commercial deployment and in Breakthrough Designation stock.

The non-motor Breakthrough Designations of 2026

Nia Therapeutics. The Boston-area company, co-founded in 2018 by University of Pennsylvania memory neuroscientist Michael Kahana (CEO) and cognitive neuromodulation researcher Daniel Rizzuto (President and CTO), received FDA Breakthrough Device Designation on 13 March 2026 for its Smart Neurostimulation System, indicated for the treatment of episodic memory loss in adult patients with prior moderate-to-severe traumatic brain injury and persistent memory deficits. The SNS is a 60-channel wireless closed-loop cortical implant. Nia describes it as the first device to receive Breakthrough Designation specifically for TBI-related memory loss, a company assertion that is not independently falsifiable because the FDA does not publicly disclose Breakthrough Designations. The SNS remains preclinical; Nia has said an Investigational Device Exemption application is planned for 2026. Inside BCI covered Nia on 5 July 2026.

ReVision Implant. The Belgian neurotechnology startup received FDA Breakthrough Device Designation in March 2026 (reported 9 March by Med-Tech Insights) for its Occular cortical visual prosthesis, designed to restore functional vision in people with severe blindness whose conditions cannot be treated with retinal implants or optic nerve therapies. Occular interfaces directly with the visual cortex, bypassing the eye and optic nerve. ReVision closed a €4 million oversubscribed seed round from private investors in May 2026, and the company has scheduled a first-in-human short-term surgical-window cohort for October 2026, with an early-stage trial in blind volunteers targeted for summer 2027, subject to regulatory approvals. CEO Frederik Ceyssens leads the company. Inside BCI covered ReVision on 27 May 2026.

Aurenar. The WashU Medicine spinout, based in St Louis Missouri and led by neurosurgeon Eric Leuthardt (CEO) and neurosurgeon Anna Huguenard (co-founder), received FDA Breakthrough Device Designation on 30 June 2026 for its V-Link System, a transauricular vagus nerve stimulator in earbud form factor. The indication is reduction of cerebral vasospasm in adults with aneurysmal subarachnoid haemorrhage, as an adjunct to intensive care management. A 27-patient WashU Medicine and Barnes-Jewish Hospital randomised controlled trial reported a greater than 40 per cent reduction in moderate-to-severe vasospasm and a roughly 20 per cent reduction in 30-day hospitalisation cost. This is cerebrovascular and ICU territory, not motor restoration. Inside BCI covered Aurenar on 30 June 2026.

Cortigent Orion (continuing Breakthrough programme with disclosed dual-lane expansion). Cortigent, the visual cortical prosthesis company that carries forward the technical lineage of Second Sight and now sits inside Vivani Medical, holds an existing FDA Breakthrough Device Designation for the Orion cortical visual prosthesis granted before 2026. Orion is a 60-electrode array implanted on the visual cortex; six subjects were implanted between January 2018 and January 2019 across the six-year Early Feasibility Study that completed in 2025. On 2 July 2026, Cortigent’s parent Vivani Medical disclosed a Cortigent stroke motor rehabilitation programme using the same core cortical-stimulation technology. Cortigent is not purely a non-motor company; it is a visual-cortex company with a secondary motor programme. Inside BCI covers Cortigent in its 2 July 2026 Vivani Medical reverse-merger coverage.

Non-motor clinical-trial milestones in the same window

Neuronoff Injectrode. The Cleveland Ohio company announced in early June 2026 the first-in-human implantation of its Injectrode peripheral nerve electrode in a DoD-funded randomised double-blind controlled trial (ClinicalTrials.gov identifier NCT07264868). The trial is sponsored by UT Health Houston, with principal investigator Argyrios Stampas at McGovern Medical School. The trial targets neurogenic bladder function through tibial nerve stimulation in patients with spinal cord injury. Injectrode is a helical platinum-iridium electrode delivered through a single 18-gauge needle under local anaesthesia and paired with an external pulse generator. The trial is designed to enrol 21 participants across three arms with primary endpoints at four and eight weeks. This is autonomic-function restoration, not motor restoration, and it is a first-in-human milestone, not a Breakthrough Designation. Inside BCI covered Neuronoff on 6 June 2026.

Coherence Neuro. The Cambridge UK company, founded 2022 as Opto Biosystems and led by Ben Woodington and Elise Jenkins, announced in June 2026 the first-in-human intraoperative implantation of its CIPHER system in three patients at Royal Melbourne Hospital during tumour resection surgery. The 30-minute intraoperative procedure places 16 threads for chronic neural recording alongside a skull-mounted button. The company closed a US$10 million seed round in November 2025 co-led by Artesian and Topology Ventures, and has drawn Neuralink ties including Matthew MacDougall (Neuralink head neurosurgeon, Coherence adviser and investor). The clinical target is oncology, specifically tumour monitoring and eventual electroceutical suppression, with a chronic-implant glioblastoma trial planned for 2027. This is the cleanest single instance of the field’s category widening in 2026: brain-tumour BCI is not a lane that existed as a commercial vertical before 2025. Inside BCI covered Coherence Neuro on 23 June 2026.

Motif Neurotech. The Houston Texas company received FDA Investigational Device Exemption approval on 27 April 2026 to begin its RESONATE Early Feasibility Study of the Motif XCS System, a minimally-invasive skull-mounted DOT implant described as blueberry-sized and wirelessly powered. The indication is treatment-resistant depression in patients with two or more failed medications. The study is planned across up to eight institutions with a 20-minute outpatient implantation procedure. TRD is a psychiatric indication, not motor. Motif does not yet have its own dedicated Inside BCI article. The primary announcement is BusinessWire dated 27 April 2026.

Peer-reviewed publications that widen the field’s clinical use case

Bath and Ulster covert consciousness diagnosis. A team led by Damien Coyle at Ulster University’s Intelligent Systems Research Centre and the University of Bath’s Institute for the Augmented Human, with lead author Naomi du Bois, published in Communications Medicine on 17 April 2026 (digital object identifier 10.1038/s43856-026-01574-x). The paper reports that combining a wearable-EEG multi-session BCI with real-time audio neurofeedback and standard behavioural assessment (CRS-R plus WHIM) lifted minimally-conscious-state detection from 39 per cent to 69 per cent across 42 brain-injury patients, with a modest trade-off in locked-in-syndrome sensitivity from 78 per cent to 67 per cent. This is a diagnostic use case in patients whose behavioural examination misses cognitive activity, not a restoration therapy. Inside BCI covered the Bath-Ulster paper on 1 July 2026.

Chalmers cortical microstimulation review. A review by Giacomo Valle at Chalmers, with co-authors Denise Oswalt, Robert A. Gaunt (Pittsburgh), Pieter Roelfsema (Netherlands Institute for Neuroscience), Charles M. Greenspon (Chicago), and Eduardo Fernandez (Miguel Hernández), published in Nature Reviews Bioengineering on 1 June 2026 (digital object identifier 10.1038/s44222-026-00449-z). The argument the review makes is that visual cortical prostheses and somatosensory cortical prostheses have converged into a single engineering discipline, with the same underlying microstimulation platform. The visual side of that argument is unambiguously non-motor. The touch side is more precisely characterised as motor-adjacent, because somatosensory cortical microstimulation is being deployed to close the loop on prosthetic-hand grasp control in people with spinal cord injury. Sensory restoration is entering commercial development as its own discipline; it is not equivalent to “beyond motor” if the touch pathway is being used to make motor prostheses work better.

Rush University ICVP. A separate visual-cortical vector: on 7 May 2026, Philip Troyk’s team at the Illinois Institute of Technology performed the third implant of the Intracortical Visual Prosthesis system at Rush University Medical Center, in a totally blind participant. The device deploys 34 wireless stimulators driving 544 electrodes. The NIH BRAIN Initiative consortium includes Johns Hopkins Wilmer, University of Chicago, UT Dallas, Rush, Microprobes, and Sigenics. Inside BCI covered the Rush ICVP on 17 May 2026 as part of a four-platform-field piece.

The motor pipeline is still expanding in the same window

The category broadening described above is not a rotation out of motor. The 2026 motor-restoration pipeline is at least as active as it was in 2025.

CorTec. The Freiburg Germany company received FDA Breakthrough Device Designation on 8 April 2026 for its Brain Interchange system for direct cortical electrical stimulation to support motor recovery in people living with chronic stroke-related impairments. The Harborview Medical Center trial in Seattle is led by Jeffrey Ojemann at the University of Washington under NIH grant UH3NS121565. CorTec’s Brain Interchange enabled a stroke patient to control a computer using cortical stimulation, per an April 2026 CorTec release. This is stroke motor rehabilitation, unambiguously a motor-restoration Breakthrough Designation. Inside BCI covered CorTec on 9 April 2026.

Neuralink CAN-PRIME. Sergeant Lee Marten of the Vancouver Police Department received a Neuralink N1 implant at University Health Network’s Toronto Western Hospital on 20 May 2026 per CBC and BetaKit reporting. Marten is Neuralink’s 26th participant worldwide, the first Canadian ALS patient, and the first human anywhere to receive the N1 via the new transdural surgical technique. ALS is a motor neuron disease. Inside BCI covered the CAN-PRIME event on 4 July 2026.

Paradromics. Paradromics announced its first Connexus BCI implant on 17 June 2026 at University of Michigan Health, in a woman with motor neuron disease, under neurosurgeons Matthew Willsey and Aditya Pandey. The Connect-One Early Feasibility Study runs at multiple US sites including UC Davis and Massachusetts General Hospital. Motor neuron disease is a motor-restoration indication. Inside BCI covered the Paradromics first implant on 17 June 2026 and covered the Paradromics Chief Clinical Officer hire (William Marks from Verily) on 7 July 2026.

Precision Neuroscience. A Johns Hopkins team led by senior author Nathan Crone (Department of Neurology and Department of Biomedical Engineering), with Precision Neuroscience as device partner, published in Neurosurgical Focus in February 2026 (PubMed 41621103, digital object identifier 10.3171/2025.11.FOCUS25908) on intraoperative use of Precision’s 1,024-channel Layer 7 micro-electrocorticography interface in four patients undergoing tumour resection near eloquent cortex. The paper reports 77.5 per cent 4-word speech-classification accuracy and 78 to 84 per cent 4-direction cursor-classification accuracy. Layer 7 is intraoperative in this study, not chronic. Both endpoints are motor-adjacent restoration.

Onward Medical. The Netherlands-and-Switzerland company closed a €40.6 million round on 16 April 2026 led by EQT Life Sciences. Onward holds ten FDA Breakthrough Designations including ARC-BCI, the thought-driven brain-computer-interface arm of its spinal-stimulation platform, granted 29 February 2024. ARC-EX has FDA 510(k) clearance for home use as of November 2025. This is upper-limb spinal cord injury motor territory. Inside BCI covered Onward’s 20 April 2026 raise announcement.

ABILITY Neurotech. The Utrecht company received Investigational Medical Device Dossier approval from the Netherlands Medical Research Ethics Committee on 26 May 2026 for the first chronic BCI implantation in ALS patients at University Medical Center Utrecht, in an INTRECOM consortium with CorTec and TU Graz. ALS motor lane.

Epia Neuro. The Michel Maharbiz team exited stealth in April 2026 with a 64-channel epidural BCI for stroke motor rehabilitation, targeting first-in-human at Lenox Hill later 2026 and FDA submission in February 2027. Stroke motor lane.

Synchron. Nicholas Opie continues as co-founder while also joining Control Bionics as a non-executive director on 14 May 2026. Synchron’s US COMMAND and Australian SWITCH studies together account for approximately ten motor-cortex participants across the two early-feasibility studies, with a pivotal trial run-up under way in 2026. Motor lane.

What “broadening” means commercially

The three non-motor FDA Breakthrough Designations of 2026 (Nia, ReVision, Aurenar), plus Cortigent’s existing Orion Breakthrough and disclosed secondary stroke motor programme, together implicate patient populations that are individually one to three orders of magnitude larger than the cervical spinal cord injury and ALS populations that anchor the motor-restoration lane. TBI-related persistent memory deficit alone reaches an estimated 4.3 million Americans per the CDC’s 2015 Report to Congress figure that Nia cites. Cortical-blindness recipients of visual prostheses number in the tens of thousands globally. Aneurysmal subarachnoid haemorrhage affects tens of thousands of ICU admissions per year in the United States alone. Treatment-resistant depression numbers in the several millions of US adults per typical epidemiological estimates. Each of these markets is larger than the classical motor-restoration commercial addressable market, and the neural data governance conversation each one opens is materially harder than the paralysis-restoration conversation.

The governance frame Inside BCI’s 4 July 2026 NMPA classification coverage described for China (every implantable BCI Class III, one narrow Class II lane for non-invasive non-AI stroke motor rehabilitation) is a device-classification framework. It is not a memory-modulation ethics framework, nor a cognitive-state-decoding privacy framework. Nia’s memory implant, Motif’s psychiatric-state device, Aurenar’s ICU vagus stimulator, and Bath and Ulster’s diagnostic covert-consciousness detector each raise policy conversations that the classical motor-restoration cohort has not had to have with regulators or patient advocates at the same intensity. The Chile constitutional neurorights framework and the state-patchwork United States neural data laws (Colorado, California, Montana, Connecticut) that Inside BCI’s ongoing coverage identifies as the four global BCI regulatory postures are being tested by the non-motor cohort more than by the motor cohort.

What to watch

Watch whether the pattern accelerates in the second half of 2026. If FDA grants two or more additional non-motor BCI Breakthrough Designations, or if a second commercial oncology BCI first-in-human lands beyond Coherence Neuro’s Melbourne cohort, the pattern moves from a directional signal into a structural one. If instead the second half of 2026 returns to motor-dominated milestones, the first-half broadening reads as a specific quarter rather than a category shift.

Watch which motor-cohort BCI companies choose to expand into non-motor indications. Cortigent’s disclosed secondary stroke motor rehab programme is the first example of a visual-cortical prosthesis company reaching back into motor territory. If Precision Neuroscience, Paradromics, or Synchron begin adding disclosed non-motor indication targets, the field is broadening from both directions simultaneously.

Watch the neural data governance conversation. Memory modulation, cognitive-state decoding, psychiatric-state stimulation, and covert-consciousness detection each surface governance questions that Colorado’s, California’s, Connecticut’s, and Montana’s state-patchwork neural data laws do not fully address. Whether US federal action, European regulatory action under the AI Act and GDPR, or Chile’s constitutional neurorights framework specifically addresses the non-motor BCI category will indicate the maturity of the governance response.

Watch capital allocation. Motor-restoration BCI capital has concentrated around Neuralink, Synchron, Paradromics, and Precision Neuroscience, with US and Gulf sovereign-linked participation. Non-motor BCI capital has been more distributed and smaller-check to date. Whether the non-motor category attracts larger single-round investments in the coming quarters will indicate whether venture and strategic capital reads the category broadening as a category-expansion opportunity or as a set of individual bets.

Sources

market synthesis FDA-Breakthrough-Device-Designation Nia-Therapeutics Aurenar ReVision-Implant Cortigent-Orion Neuronoff Coherence-Neuro Motif-Neurotech Rush-ICVP Bath-Ulster Chalmers-Valle CorTec Neuralink Paradromics Precision-Neuroscience Onward-Medical ABILITY-Neurotech Epia-Neuro